The imperative to reduce the high cost of goods sold (COGS) for biologics, particularly in the face of rising biosimilar competition and payer scrutiny, is driving a revolution in manufacturing strategies centered on process intensification and the shift toward continuous production. Process intensification involves increasing the productivity of a given bioreactor volume through techniques like high-density cell culture, perfusion technology, and multi-column chromatography, effectively allowing manufacturers to produce more product with the same or a smaller physical footprint. The ultimate goal of this trend is Continuous Manufacturing (CM), where raw materials are fed into the process and the finished product is drawn off in a steady, uninterrupted stream. CM offers substantial advantages over traditional batch processing, including significantly smaller equipment, reduced capital expenditure, lower labor costs, and most crucially, higher, more consistent product quality due to tighter process control. This technological leap is fundamentally reshaping the design of future GMP biologics facilities and the skillsets required to operate them.

However, the adoption of continuous manufacturing is not without significant hurdles. It requires entirely new equipment designs, complex process analytical technologies (PAT) for real-time quality control, and a significant commitment to re-validating processes with regulatory bodies, who are still developing guidance for these novel systems. This transition is capital-intensive and requires a deep level of expertise in process modeling and automation. For specialized service providers, like CDMOs, this means investing heavily in pilot-scale CM capabilities to demonstrate feasibility to their clients and establishing the digital backbone necessary for the highly automated environment. The complexity and risk involved ensure that only companies with significant resources and a clear long-term strategy will successfully implement these advanced technologies. The strategic decision to specialize in high-growth segments requires a clear understanding of the sub-market structure. A detailed breakdown of the Veterinary Laboratory Testing Market Segment dynamics—analyzing the growth of molecular diagnostics versus traditional chemistry—can provide critical business intelligence to justify and focus the large-scale investments required for advanced manufacturing technology.